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Pre-trilostane and three-hour post-trilostane
cortisol to monitor trilostane therapy in dogs
L. Macfarlane, T. Parkin, I. Ramsey
It is recommended that trilostane therapy of canine hyperadrenocorticism is monitored
using an ACTH stimulation test, however this has never been validated. Three cortisol
concentrations (pre-trilostane, 3-hour posttrilostane and 1-hour post-ACTH stimulation) were
compared to a clinical score obtained from an owner questionnaire. There were 110 sets of
3 cortisol measurements and questionnaires obtained from 67 trilostane treated dogs.
Questionnaire results were used to classify each dog as well or unwell. Well dogs were then
categorised as having excellent, moderate or poor hyperadrenocorticism control, using
thresholds produced by 14 independent veterinarians. Correlation co-efﬁcients were used to
compare the three cortisol concentrations to the owner score and the Kruskal Wallis and
Mann-Whitney U tests were used to compare the three cortisol concentrations between
categories of control. Cortisol cut-off values between signiﬁcantly different categories were
determined using ROC curves. Pre-trilostane and 3-hour post-trilostane cortisol were better
correlated to the owner score and had cut-offs to differentiate between categories of control
that had superior sensitivity and speciﬁcity results, than the post-ACTH cortisol. Iatrogenic
hypoadrenocorticism was not detected in any unwell dog. This study shows that the
pre-trilostane and 3-hour post-trilostane cortisol are potentially better monitoring methods
than the ACTH stimulation test.
Trilostane is a competitive inhibitor of the enzyme
3-β-hydroxysteroid dehydrogenase, resulting in reduced synthe-
sis of glucocorticoids and, to a lesser extent, mineralocorticoids
(Potts and others 1978). Trilostane is licensed in many countries
to treat pituitary and adrenal-dependent hyperadrenocorticism
(HAC) (Vetoryl, Dechra). The manufacturer recommends a
starting dose of 2 mg/kg once daily and frequent monitoring
using a combination of history, physical examination and
serum biochemical (including electrolytes) testing in combin-
ation with an adrenocorticotrophic hormone (ACTH) stimula-
tion test started four-hour to six-hour post dosing
(VMD 2016).
The ACTH stimulation test has been widely used and recom-
mended as the monitoring method of choice for dogs receiving
trilostane (Neiger and others 2002, Braddock and others 2003,
Bell and others 2006, Vaughan and others 2008, Bonadio and
others 2014); however, it has never been validated for this
purpose. As trilostane is relatively short acting, there are concerns
regarding the variation in results depending on the time since the
last dose of trilostane (Bell and others 2006, Midence and others
2015) and whether results reﬂects clinical control (Wehner and
others 2014). Recently, it has been suggested that as the nadir
cortisol occurs three hours after trilostane administration, the
ACTH stimulation test should be started two to four hours post
dosing (Griebsch and others 2014).
Alternative methods of monitoring dogs receiving trilostane
have been investigated with varying success. These methods
include baseline cortisol (Cook and Bond 2010), endogenous
ACTH and cortisol/ACTH ratio (Burkhardt and others 2013),
haptoglobin (McGrotty and others 2005, Arteaga and others
2010) and the urine corticoid:creatinine ratio (UCCR) before and
after trilostane (Galac and others 2009). In all of these studies,
control was ultimately deﬁned by the results of the post-ACTH
stimulation cortisol and the owners’ perception of clinical
control is often not well described.
Tetracosactide (synthetic ACTH) can be expensive in some
countries and has limited availability. Additionally, at high con-
centrations, it causes adrenal gland degeneration in rats
(Burkhardt and others 2011). An effective monitoring tool for
dogs receiving trilostane that does not require tetracosactide
would be of considerable beneﬁt.
The aim of this study was to develop an owner questionnaire
to assess clinical control of dogs with HAC receiving trilostane.
This measure of clinical control was then compared with
the one-hour post-ACTH stimulation cortisol concentration
(post-ACTH), the three-hour post-trilostane cortisol (also
known as the baseline cortisol) (Cook and Bond 2010, Burkhardt
and others 2013) and a novel monitoring method measuring cor-
tisol concentration before trilostane was administered (pre-
trilostane cortisol).
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Materials and methods
Case selection
Client-owned dogs were prospectively recruited from November
2013 to June 2014 from clinical practices throughout the UK
including dogs referred to the Small Animal Hospital,
University of Glasgow. External practices were recruited
through a combination of personal contact with the authors
and advertisement on a small animal internal medicine society
website (SAMSoc 2013). Dogs were included if they had a pre-
existing diagnosis of naturally occurring HAC that had been
treated with a stable dose of commercially available trilostane
(Vetoryl, Dechra) for at least 10 days. The results of testing to
establish the original diagnosis and differentiation between
adrenal and pituitary HAC, including endocrine testing and
abdominal ultrasound results, were obtained retrospectively.
This was through a combination of computer-based records
and from telephone contact with the primary veterinary prac-
tice. The diagnosis of HAC was based on a combination of
history, physical examination ﬁndings, haematology, biochemis-
try, urinalysis and endocrine testing (low-dose dexamethasone
suppression test (LDDST), ACTH stimulation test or UCCR),
which were compatible with HAC (Feldman 1983, Behrend and
Kemppainen 2001, Behrend and others 2013). If the distinction
between adrenal-dependent HAC and pituitary-dependent HAC
was made, then it was recorded. Pituitary-dependent HAC was
diagnosed if any of the following criteria were met; normal or
high concentrations of endogenous ACTH, cortisol concentra-
tions four-hour post-dexamethasone suppression below the
lower limit of detection of the laboratory or less than 50 per
cent baseline, pituitary enlargement on MRI or CT, or bilat-
erally symmetric normal-sized glands or adrenomegaly was con-
sidered consistent with (Barthez and others 1995, Feldman and
others 1996, Van Liew and others 1997, Gould and others 2001,
Melian and others 2010). In contrast, low or undetectable
endogenous ACTH or an adrenal tumour with contralateral
atrophy of the other adrenal gland was considered consistent
with adrenal-dependent HAC (Barthez and others 1995,
Feldman and others 1996, Van Liew and others 1997, Gould
and others 2001, Melian and others 2010).
Throughout the study, the primary veterinarian remained in
charge of case management. All changes in dose were made at
their discretion and based on their own clinical assessments of
the case.
Questionnaire
The primary veterinarian responsible for the care of each dog
and the owner provided information regarding the signalment,
date of diagnosis of HAC, trilostane dose (including frequency,
duration, both in total and at the current dose), time of last tri-
lostane administration, weight, abnormal physical examination
ﬁndings, concurrent conditions and medications. Dogs were
excluded if they were receiving medication or had a concurrent
disease or physical examination ﬁndings that were likely to sig-
niﬁcantly impact on the cortisol results (e.g. pyrexia, glucocortic-
oid treatment (oral or topical) or severe illness such as malignant
neoplasia) or if the owner had not given the dog its normal dose
of trilostane the previous day. Dogs that had stable concurrent
conditions such as hypothyroidism were not excluded. A ques-
tionnaire was developed from an ad hoc survey of practising
veterinarians of the terms associated with HAC and their relative
importance in assessing the clinical control of trilostane-treated
dogs. The questionnaire was completed by the owner and was
designed to both evaluate the owners’ perception of the effect-
iveness of trilostane therapy and to highlight any dog that was
unwell. Eight questions using a Likert scale response were used
to assess thirst, urine volume, appetite, panting, exercise toler-
ance, coat quality, demeanour, gastrointestinal signs and the
owner ’s overall impression of the HAC control. A ninth question
(Q7) was directed at identifying other signs of progression of
HAC, and for this the respondent was asked to tick all responses
that applied to their pet. Weighted scores with a minimum total
of 4 and a maximum total of 28 points available were retrospect-
ively assigned to the answers that evaluated the effectiveness of
HAC control by two of the authors (LM and IR). Answers that
implied an increased severity of HAC signs resulted in a higher
score assignment. No score was given to any answer that was a
possible sign of illness; instead, the abbreviation PI (possible
illness) was assigned each time an owner gave such a response.
There were two answers that were equivocal (Q5a and Q9a) (i.e.
the authors considered they could equally be consistent with
illness or under control of HAC). These answers were given a
score and PI was also assigned. A copy of the owner question-
naire, the scoring system and PI assignment are shown in online
supplementary appendix 1. The information recorded on the
questionnaire and from hospital records and contact with the
primary veterinary practice were transferred to a database (Excel;
Microsoft 2010). Dogs were excluded if they had incomplete or
missing data.
The scores from the questionnaire were then retrospectively
grouped into categories of clinical control that were deﬁned by
the following method. A group of 14 clinicians (6 junior clinical
training scholars in small animal medicine and surgery with at
least two years of relevant clinical experience, 4 ECVIM-CA resi-
dents in small animal internal medicine and 4 European specia-
lists in veterinary internal medicine (DipECVIM-CA)) were
individually asked to review answers from the completed owner
questionnaire. A random number generator (Randomizer 2015)
was used to group 30 questionnaires selected to represent a range
of answers, into 10 groups of 3 each, and each veterinarian was
given 3 groups of 3 questionnaires to assess (total 9 per person).
The dog and owner details and the score from the questionnaire
and/or PI assigned to each answer were not available to the
clinicians.
The clinicians were ﬁrst asked to categorise each dog as being
well or unwell on the basis of the owners’ answers. The clini-
cians’ response was assessed, and a ﬁnal category was reached by
calculation of the mode for each of the 30 individual dogs. In
both the dogs classiﬁed as well and those classiﬁed as unwell,
the number of PI answers in each group was calculated. Using
the results, the minimum number of PI answers required to clas-
sify a dog as unwell for the remainder of the study population
was established.
The clinicians were then asked to group the well dogs into
one of three categories of clinical control. The ﬁrst was excellent
control (deﬁned as no dose increase likely required). The second
two categories were degrees of under control; reasonable (small
dose increase likely required) and poor control (large dose
increase likely required). The clinicians’ answers were assessed,
and a ﬁnal category was reached by calculation of the mode for
each of the individual tests. The numerical scores that had been
assigned to each dog by the authors were compared across the
three categories of clinical control. Using the results, ranges of
scores for each category of clinical control were established and
then retrospectively applied to the remainder of the study
population.
Blood sampling
Dogs were presented to the examining veterinary surgeon before
receiving their trilostane dose. A blood sample was taken at the
time of presentation (pre-trilostane). The trilostane dose was then
administered, along with the dog’s normal meal provided by the
owner. Three hours after the trilostane had been given, an ACTH
stimulation was performed by taking a blood sample (three-hour
post-trilostane) and then administering 5 μg/kg of tetracosactide
(Synacthen; Alliance) intravenously. A third blood sample was
taken one hour after tetracosactide was administered
(post-ACTH). The ACTH stimulation test was started at three
hours because the cortisol nadir following trilostane administra-
tion occurs at this time in most dogs (Lehnert 2007, Griebsch and
others 2014). The three blood samples were submitted to a single
commercial veterinary laboratory (Veterinary Diagnostic Services,
University of Glasgow) that takes part in a variety of quality
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assurance schemes including those run by Randox Laboratories
and the European Society of Veterinary Endocrinology. Cortisol
concentration was measured concurrently on all three samples
using a competitive chemiluminescent enzyme immunoassay
(Immulite 2000 cortisol; Siemens Healthcare, UK and Ireland)
(Singh and others 1997) that has been validated for dogs and is
widely used in laboratories throughout the world. Daily quality
controls were performed in accordance with the manufacturer’s
instructions. Only results from samples ran on the same day in
which paired standards had a coefﬁcient of variation (CV per cent)
less than 6 per cent were included in the analyses. The three corti-
sol results were transferred to the electronic database (Excel;
Microsoft 2010) containing the dog details and owner responses
from the questionnaire. The clinicians in charge of each case were
provided with the three cortisol concentration results, but not the
scores from the completed owner questionnaire or the categorisa-
tion (which were all applied retrospectively).
Unwell dogs
The dogs that were classiﬁed as unwell were further divided into
two groups. The ﬁrst included those with pre-trilostane or
post-ACTH cortisol less than 40 nmol/l (which suggested they
were unwell due to possible iatrogenic hypoadrenocorticism or
another concurrent condition) and the second those with pre-
trilostane or post-ACTH cortisol greater than 40 nmol/l (which
suggested they were unwell secondary to another concurrent
condition). The results from all these unwell dogs were not
included in further analyses but assessed individually.
Statistical analyses
Statistical analyses were performed using commercially available
software (IBM SPSS Statistics V.22, IBM; and Stata V.12.1,
StataCorp). All continuous variables were assessed for normality
using the Anderson-Darling method. The median values are
reported for variables that were not normally distributed and the
mean for variables that were normally distributed.
Pearson’s correlation coefﬁcient was calculated to determine
the correlation between the three absolute cortisol results (pre-
trilostane, three-hour post-trilostane and post-ACTH) to each
other and the total owner score in the well dogs.
In the well dogs, the Kruskal-Wallis test was used to compare
the cortisol concentrations between the three categories of clin-
ical control, as deﬁned by the results of the owner questionnaire.
If a signiﬁcant difference was found, a Mann-Whitney U test
was performed between the three groups. A P value of <0.05
was considered signiﬁcant.
If cortisol results were signiﬁcantly different between groups,
receiver operating characteristic (ROC) curves were constructed
to evaluate the sensitivity and speciﬁcity of the pre-trilostane,
three-hour post-trilostane and the post-ACTH stimulation corti-
sol at discriminating between the groups. ROC curves displayed
sensitivity versus 1-speciﬁcity such that the AUC varied from
0.5 to 1.0, with higher values indicating increased discriminatory
ability. Optimal cut-offs were determined such that the speciﬁ-
city was maximised while maintaining the sensitivity and there-
fore reducing the likelihood of unnecessary dose increases.
Univariate and multiple stepwise mixed-effects linear regression
analyses were used to assess any association between the three
cortisol results (pre-trilostane, three-hour post-trilostane and
post-ACTH) and the total owner score and the following
factors: age, sex, bodyweight, total daily dose (mg/kg), dose fre-
quency, duration at current dose (months), total duration of
therapy (months), being well or unwell, type of HAC (adrenal or
pituitary) and visit number. In the univariate analysis, a P value
<0.2 was considered potentially signiﬁcant and the factor was
taken forward to multiple regression analysis. Variables were
ordered by P value (smallest to largest) before sequential inser-
tion into the multivariable models. Variables were retained in
the models if P<0.05. Mixed-effects linear regression analysis
was used to account for any potential effect of clustering within
dog as some dogs were included in the database on more than
one occasion.
Results
Dog signalment, method of diagnosis and visit
information
In total, 110 tests were included from 67 individual dogs. A total
of 37 tests were performed at the University of Glasgow and 73
tests were performed at external practices. In total, 94 tests were
performed on dogs receiving once-daily trilostane and 16 on dogs
receiving twice-daily trilostane. There were 6 female entire dogs,
38 female neutered dogs, 11 male entire and 12 male neutered
dogs. At ﬁrst presentation, the mean age was 11.19 years (sd
±2.53). The median weight was 11.85 kg (range 2.3–40 kg). The
method of diagnosis was known in all dogs. The ACTH stimula-
tion test was reported as the conﬁrmatory test in 48/67 dogs and
low-dose dexamethasone suppression in 19/67 dogs. There were
4 dogs diagnosed with adrenal-dependent and 23 dogs with
pituitary-dependent HAC. In 40 dogs, the distinction was not
made. To make the distinction, a combination of one or more of
the following was used: abdominal ultrasound assessing adrenal
size and symmetry in 17/27 dogs, LDDST in 9/27 dogs,
endogenous ACTH in 4/27 dogs and MRI in 2/27 dogs. The
median total daily dose of trilostane of all 110 tests was
3.47 mg/kg (range 0.67–16.51 mg/kg). The median duration of
therapy before the ﬁrst presentation was 4.5 months (range
0.33–36 months) and at the current dose was 2 months (range
0.33–36 months). The median of the total duration of therapy
for all visits was 11.15 months (range 0.33–72 months).
There were 22 dogs that had more than one test performed
consecutively; 9 dogs had 2 tests, 6 dogs had 3 tests performed, 6
dogs had 4 tests and 1 dog had 5 tests. Within this group, there
were eight dogs that did not have a total daily dose or frequency
change at any subsequent visit. There was one dog that had a
frequency increase and one dog that had a frequency decrease,
without a total daily dose change at a subsequent visit. A
further ﬁve dogs had a total daily dose increase and three dogs
had a dose decrease. There were three dogs that had both a fre-
quency and dose increase at subsequent visits and one dog had a
frequency and dose decrease.
Concurrent medication
In total, 15 of the 67 dogs received medication other than
trilostane at one or more visits. These medications included
meloxicam (Metacam; Boehringer) in three dogs and subcutane-
ous lente insulin injections (Caninsulin; Intervet) were reported
in two dogs. Oral gabapentin (Neurontin; Pﬁzer), phenylpropa-
nolamine (Propalin; Vetoquinol), benazepril (Fortekor; Elanco),
clopidogrel (Plavix; Sanoﬁ), tramadol (Tramadol; Actavis), levothyr-
oxine (Thyforon; Dechra), ursodeoxycholic acid (Destolit;
Norgine), amlodipine (Istin; Pﬁzer), a preparation containing green
lipped mussel and glucosamine HCl (Yumove; Lintbells)
and a preparation containing S-adenosyl-L-methionine, silybin,
vitamin E and vitamin C (Samylin; Vetplus) were each pre-
scribed in one dog.
Owner questionnaire results
From analysis of the clinicians’ review of 30 of the owner ques-
tionnaires, if an owner answered three or more PI answers, then
the dog was classiﬁed as being unwell. Using this protocol, 17
questionnaires from 11 dogs were classiﬁed unwell.
The total owners’ scores for the 93 tests from 62 well dogs
ranged from 5 to 25 (median=13). From analysis of the clini-
cians’ assessments, the HAC control in the well dogs was further
classiﬁed as excellent if they scored between 4 and 11, reasonable
if they scored between 12 and 16 or poor control if they scored
17 or greater. Using this system, the control of HAC in 37 well
dogs was classiﬁed as excellent, 33 as reasonable and 23 as poor.
It was not possible for a test to score less than 4.
After analysis of the results from only the ﬁrst visit of each
of the 67 dogs, questionnaire answers indicated that 6 dogs were
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unwell and 61 dogs were well. Of these 61 well dogs, 23 were
classiﬁed as having excellent control, 23 having reasonable
control and 15 having poor control.
When the category allocation by the clinicians to the ques-
tionnaires was analysed, it emerged that all of the questionnaires
were reviewed at least once by either an ECVIM-CA diplomate
or a resident. When the results from only the ECVIM-CA diplo-
mates or residents were compared with the results from all clini-
cians (i.e. including junior clinical training scholar), there was
complete agreement in 28/30 (93.3 per cent) of the question-
naires. In the two questionnaires where there was disagreement,
this was due to the inability to allocate the questionnaire into
one category as the two ECVIM-CA diplomates/residents gave a
different category of control.
Cortisol results: tests performed on well dogs
Absolute cortisol concentrations: all 93 tests
All three cortisol results were signiﬁcantly correlated to the total
owner score (pre-trilostane cortisol r=0.38, P<0.001; three-hour
post-trilostane cortisol r=0.32, P=0.002; and post-ACTH stimu-
lation cortisol r=0.27, P=0.01). All three cortisol results were
also signiﬁcantly correlated to each other (pre- and three-hour
post-trilostane to post-ACTH r=0.56, P<0.001, r=0.68,
P<0.001, respectively, and pre- to three-hour post-trilostane
r=0.77, P<0.001).
When assessing differences between the individual groups,
all three cortisol results were signiﬁcantly lower in the dogs with
excellent control compared with those with poor control. The
pre-trilostane and three-hour post-trilostane cortisol were signiﬁ-
cantly lower in dogs with excellent compared with those with
reasonable control. The post-ACTH cortisol was not signiﬁ-
cantly different between dogs with excellent compared with
those with reasonable control. None of the three cortisol results
was signiﬁcantly different between dogs with reasonable control
and those with poor control. Table 1 summarises the median and
range of cortisol concentrations including relevant P values,
between the clinical groups.
As there was no signiﬁcant difference between the cortisol
results of the dogs with reasonable control and poor control, and
given both groups were deﬁned as dogs with varying degrees of
under control, test results from these groups were combined into
one category (undercontrolled n=56). The pre-trilostane, three-
hour post-trilostane and post-ACTH cortisol were all signiﬁ-
cantly lower in the dogs with excellent control compared with
those that were undercontrolled (reasonable and poor control
combined) (P<0.001, P<0.001 and P=0.027, respectively)
(Fig 1). ROC curve analysis of pre-trilostane, three-hour post-
trilostane and post-ACTH cortisols to distinguish those with
excellent control from undercontrolled dogs had an AUC of 0.73,
0.73 and 0.64, respectively (Fig 2). Using a pre-trilostane cortisol
of ≤138 nmol/l to distinguish those dogs that had excellent
control from those that were undercontrolled gave a sensitivity
of 55.4 per cent and a speciﬁcity of 86.5 per cent. Using three-
hour post-trilostane cortisol of ≤62 nmol/l to distinguish those
dogs that had excellent control from those that were undercon-
trolled gave a sensitivity of 58.9 per cent and a speciﬁcity of 81.1
per cent. Using post-ACTH stimulation cortisol of ≤130 nmol/l
to distinguish those dogs that had excellent control from under-
controlled gave a sensitivity of 41.1 per cent and a speciﬁcity of
70.3 per cent.
Absolute cortisol concentrations: analysis of the ﬁrst visit
The cortisol results from the ﬁrst visit of each of the 61 individ-
ual dogs that were well were analysed. The pre-trilostane and
three-hour post-trilostane cortisol were signiﬁcantly correlated
to the total owner score (r=0.344, P=0.007, and r=0.316,
P=0.013, respectively). Unlike the complete data set, the
post-ACTH stimulation cortisol was not signiﬁcantly correlated
to the total owner score (r=0.145, P=0.263).
The pre-trilostane and three-hour post-trilostane cortisol
were signiﬁcantly lower in dogs with excellent control compared
with those with reasonable control and those with excellent
control compared with those with poor control. The pre-
trilostane and three-hour post-trilostane cortisol were not signiﬁ-
cantly different between those with reasonable control and
those with poor control. Again, in contrast to the complete data
set, the post-ACTH stimulation cortisol was not signiﬁcantly
different between any of the three groups. Table 2 summarises
the median and range of cortisol concentrations, including rele-
vant P values between the clinical groups.
When the dogs with reasonable and poor control were
grouped together (undercontrolled group), the pre-trilostane and
three-hour post-trilostane cortisol results were signiﬁcantly
lower in dogs that had excellent control compared with the
undercontrolled group (P=0.020 and 0.033, respectively). Again,
in contrast to the complete data set, the post-ACTH cortisol was
not signiﬁcantly different between dogs that had excellent
control and the undercontrolled group. ROC curve analysis of
the pre-trilostane and three-hour post-trilostane cortisol to dis-
tinguish those with excellent control from undercontrolled dogs
had an AUC of 0.717 and 0.693, respectively. Using a pre-
trilostane cortisol of ≤138 nmol/l to distinguish those dogs that
had excellent control from those that were undercontrolled gave
a sensitivity of 55.3 per cent and speciﬁcity of 87.0 per cent.
Using three-hour post-trilostane cortisol of ≤62 nmol/l to distin-
guish those dogs that had excellent control from those that were
undercontrolled gave a sensitivity of 52.6 per cent and a speciﬁ-
city of 73.9 per cent.
Cortisol results: tests performed on unwell dogs
There were 17 tests in 11 dogs categorised as unwell based on
the results of the owner questionnaire. No owner answered 3a,
4d or 8a at any visit. The pre-trilostane was greater than
40 nmol/l in all dogs (range 46–508 nmol/l), as was the
post-ACTH stimulation cortisol (range 52–375 nmol/l). It was
therefore concluded that they were not unwell due to iatrogenic
hypoadrenocorticism.
Low cortisol results
There were 31 results, all from well dogs, in which the
three-hour post-trilostane cortisol was less than 40 nmol/l
(range <7–39 nmol/l). In 2/31 tests, the pre-trilostane cortisol
was concurrently low and in 6/31 tests the post-ACTH stimula-
tion cortisol was concurrently low, which are described below.
TABLE 1: All 93 test results
Excellent control
(n=37)
Reasonable control
(n=33)
Poor control
(n=23)
P value (only significant results
shown)
Pre-trilostane cortisol (nmol/l) median (range) 85 (22–323)*# 139 (54–480)* 155 (39–657)# 0.002*
0.001#
3-hour post-trilostane cortisol (nmol/l) median (range) 41 (<7–198)¥ † 74 (12–276)¥ 85 (13–428) † 0.001¥
0.003†
Post-adrenocorticotrophic hormone cortisol (nmol/l) median
(range)
76 (7–353)Ø 103 (24–342) 121 (41–419)Ø 0.010Ø
The median and range of cortisol concentrations in the three categories of clinical control
*,#,¥,Ø,† depict cortisol results that are significantly different and associated P values are shown
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There were eight post-ACTH stimulation cortisol concen-
trations that were less than 40 nmol/l (range 7–34 nmol/l).
There were six pre-trilostane cortisol concentrations that were
less than 40 nmol/l (range 22–39 nmol/l). Also, 5 of these 14
results were from the same dog, tested on three separate occa-
sions. The other nine results were from different dogs.
Therefore, in total there were 10 dogs that had a cortisol con-
centration less than 40 nmol/l at either or both time points.
All dogs were classiﬁed as well based on the results of the
owner questionnaire.
Follow-up information was obtained for all 10 dogs. All deci-
sions regarding dose and frequency alterations were made by the
primary veterinarian responsible for the care of each dog. There
were eight dogs alive at the time of writing (median follow-up
584 days, range 525–663 days). In 4/8 dogs, the dose of trilostane
was reduced after receiving the test results (three when
post-ACTH cortisol and one when both the pre-trilostane and
post-ACTH cortisol concentrations were less than 40 nmol/l). In
two out of these four dogs, subsequent post-ACTH stimulation
cortisol remained less than 40 nmol/l and the trilostane was
stopped. In one of these dogs, the clinical signs of HAC returned
within seven days and there was no record of subsequent clinical
signs of HAC in the other. In the remaining 4/8 dogs, the dose of
trilostane was initially not altered after receiving the cortisol
results (2/4 when pre-trilostane and 2/4 when post-ACTH corti-
sol was less than 40 nmol/l). Subsequent follow-up revealed that
in two of these four dogs the dose was reduced after the next
visit, based on the results of repeat ACTH stimulation performed
three to six hours after trilostane was administered. No record of
clinical signs before or subsequent to this alteration was recorded
and both dogs remained on the lower dose at the time of
writing. In the remaining 2/4 dogs, the dose remained unaltered.
In one of these two dogs, where only the pre-trilostane cortisol
was less than 40 nmol/l, signs of acute gastroenteritis developed
three months after the test. Hyponatraemia was detected at this
stage; however, the potassium concentration and sodium:potas-
sium ratio were normal. Trilostane was temporarily stopped but
restarted at the same dose after successful treatment of the
gastroenteritis. The other dog has remained clinically stable and
both dogs receive the same dose of trilostane at the time of
writing. In the dog with three separate tests with low cortisol
results, two tests had both pre-trilostane and post-ACTH corti-
sol less than 40 nmol/l. One test had only pre-trilostane cortisol
less than 40 nmol/l. The dose was reduced after each of the three
test results. The ﬁrst time only the pre-trilostane cortisol was
low. Although the owner questionnaire indicated that the dog
was well, after this dose reduction they reported the dog became
brighter. The dose was reduced at both subsequent tests, in
which both the pre-trilostane and post-trilostane were low. The
owner reported on both occasions and at all subsequent visits
that the dog was clinically normal and continues to receive the
reduced dose for a further seven months.
Within this group of dogs, there were two dogs that had
euthanasia performed during the follow-up period. One dog that
had a post-ACTH cortisol less than 40 nmol/l but did not have a
subsequent dose reduction had euthanasia performed 612 days
after the result due to a pituitary macroadenoma. The other that
had a pre-trilostane cortisol less than 40 nmol/l and had a subse-
quent dose reduction was euthanased 178 days after the result
due to faecal and urinary incontinence. In both cases, iatrogenic
hypoadrenocorticism was excluded immediately before euthan-
asia through a combination of haematology, biochemistry and
endocrine testing.
Univariate and multivariable mixed-effects linear
regression analysis
As the distinction between adrenal-dependent and pituitary-
dependent HAC was only made in 27/67 dogs, this factor was
not carried forward to multivariable analysis and only results
with a P<0.05 from univariate analysis were considered
signiﬁcant.
In the univariate analysis of entire females, total duration of
therapy and duration of current dose had signiﬁcant (P<0.2)
associations with pre-trilostane cortisol and were investigated in
a multivariable model. In the ﬁnal model, the results from the
six female entire dogs compared with the remaining results were
found to be associated with pre-trilostane cortisol (P<0.05).
This model showed that pre-trilostane cortisol was a median of
93 nmol/l higher in entire female dogs compared with the rest of
the population.
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FIG 1: Box and whisker plots of pre-trilostane, three-hour
post-trilostane and post-adrenocorticotrophic hormone (ACTH)
cortisol concentrations divided into two groups of clinical control, an
excellent (n=37) and an undercontrolled group (n=56) formed from
the moderately and poorly controlled groups. The lower and upper
boundaries of the box represent ﬁrst and third quartiles of the data,
respectively, with the line within the box representing the median.
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Signiﬁcantly different results are indicated by connecting horizontal
lines with the P values shown above
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FIG 2: Receiver operating characteristic (ROC) curves assessing
pre-trilostane, three-hour post-trilostane and post-adrenocorticotrophic
hormone (ACTH) cortisol concentrations as a predictors of clinical
control (excellent versus undercontrolled). The AUC for pre-trilostane
cortisol was 0.73 (95% CIs) 0.62 to 0.83), three-hour post-trilostane
cortisol was 0.73 (95% CI 0.62 to 0.84) and post-ACTH cortisol was 0.64
(95% CI 0.52 to 0.75)
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In the univariate analysis dose (mg/kg), duration of current
dose, total duration of therapy and female entire had signiﬁcant
(P<0.2) associations with the three-hour post-trilostane cortisol
and were investigated in a multivariable model. In the ﬁnal
model, total duration of therapy and female entire were found
to be associated with the three-hour post-trilostane cortisol
(P<0.05). This model showed that for every one-month
increase in duration of therapy, the three-hour post-trilostane
cortisol was a median of 1 nmol/l lower. In addition, the three-
hour post-trilostane cortisol was a median of 46 nmol/l higher
in the female entire dogs compared with the rest of the
population.
In univariate analysis age, total dose (mg/kg), duration of
current dose and total duration of therapy had signiﬁcant
(P<0.2) associations with the post-ACTH cortisol and were
investigated in a multivariable model. In the ﬁnal model, total
duration of therapy and total dose mg/kg were found to be asso-
ciated with post-ACTH cortisol (P<0.05). The model showed
that for every one-month increase duration of therapy, the
post-ACTH cortisol was a median of 2 nmol/l lower. In addition,
for every 1 mg/kg increase in total dose, the post-ACTH cortisol
was a median of 5 nmol/l higher.
In univariate analysis, duration of current dose, total dur-
ation of therapy, female entire and male entire had signiﬁcant
(P<0.2) associations with the total owner score in the results
from well dogs and were investigated in a multivariable model.
In the ﬁnal model, the duration of current dose and female
entire dogs compared with the remaining results were found to
be associated with the total owner score (P<0.05). The model
showed that for every increase in one month of therapy at the
current dose, the total owner score decreased by a median of
0.14. In addition, the total owner score was a median of 5.1
higher in the results from female entire dogs compared with the
rest of the population. Mixed-effects linear regression analysis
demonstrated that there was no signiﬁcant clustering within dog
identity, and therefore, the inclusion of multiple visits from
some dogs did not introduce a signiﬁcant bias. Tables 3 and 4
summarise the results from univariate and multivariable
mixed-effects linear regression analysis.
Discussion
The study showed that the pre-trilostane, three-hour post-
trilostane and post-ACTH cortisol correlated with clinical
control as deﬁned by the veterinary assessment of owners’
responses in a questionnaire. All three cortisol results were sig-
niﬁcantly lower in the dogs classed as having excellent control
compared with those classed as being undercontrolled (reason-
able and poor control combined). The pre-trilostane and three-
hour post-trilostane cortisol were better than the post-ACTH
stimulation cortisol at differentiating between the dogs with
excellent control and those that were undercontrolled.
The aim of trilostane therapy should be to satisfactorily
control clinical signs, without resulting in iatrogenic hypocorti-
solism. This study questions the existing recommendations that
TABLE 2: Test results from first visit only
Excellent control
(n=23)
Reasonable control
(n=23)
Poor control
(n=15)
p Value (only significant results
shown)
Pre-trilostane cortisol (nmol/l) median (range) 83 (26–323)*# 139 (54–480)* 155 (39–657)# 0.013*
0.02#
3-hour post-trilostane cortisol (nmol/l) median (range) 38 (<7–198)¥ † 59 (20–276)¥ 94 (25–428)† 0.032¥
0.033†
Post-adrenocorticotrophic hormone cortisol (nmol/l) median
(range)
102 (7–353)Ø 86 (24–196) 119 (41–419)Ø 0.1Ø
The median and range of cortisol concentrations in the three categories of clinical control
*,#,¥,Ø,† depict cortisol results that are significantly different and associated P values are shown
TABLE 3: Univariate analysis investigating associations between factors and the pre-trilostane, the post-ACTH and the total owner
score
Pre-trilostane cortisol
(nmol/l)n=110 dogs
3-hour post-trilostane
cortisol (nmol/l)n=110
dogs
Post-adrenocorticotrophic
hormone cortisol (nmol/l)
n=110 dogs
Total owner score (well
dogs only)n=93 dogs
Factor Coefficient P value Coefficient P value Coefficient P value Coefficient P value
Age (years) −1.43 0.71 −2.72 0.29 −4.55 0.15* −0.18 0.34
Dose frequency 26.02 0.31 11.27 0.52 −13.65 0.53 −1.11 0.37
Well/unwell 1.80 0.94 9.46 0.58 16.55 0.43 N/A N/A
Weight (kg) −0.84 0.44 −0.68 0.36 −0.53 0.57 −0.07 0.24
Dose (mg/kg) 3.50 0.25 3.770 0.06* 4.92 0.05* 0.08 0.63
Duration at current dose (months) −1.83 0.11* −1.84 0.02* −2.25 0.02* −0.15 0.01*
Total duration of therapy (months) −1.16 0.13* −1.27 0.014* −2.19 <0.01* −0.09 0.02*
Type** (pituitary versus adrenal) 41.6 0.14 35.35 0.07 48.92 0.05 2.90 0.06
Sex (compared with female entire (n=8))
Female neutered (n=59) −82.95 0.02* −41.84 0.07* −26.00 0.39 −0.52 <0.01*
Male entire (n=22) −91.11 0.01* −46.18 0.07* −31.25 0.34 −628 <0.01*
Male neutered (n=21) −122.46 <0.01** −71.45 0.01* −31.27 0.34 −4.71 0.02*
Female entire versus all
Female entire versus all 92.83 0.01* 48.87 0.04* 5.35 <0.01*
Visit number (compared with visit 1)
2 −20.710 0.37 −11.28 0.47 23.93 0.22 −0.18 0.89
3 −12.273 0.67 −11.78 0.54 5.22 0.83 −0.27 0.86
4+ −25.744 0.46 14.47 0.55 37.40 0.21 −1.83 0.37
* indicates results with P<0.2 that were considered potentially significant
** indicates that because the distinction was only made in 27/67 dogs, with only 4/27 adrenal dependent, results were not carried forward to multivariable analysis and
only results P<0.05 were considered significant for this factor
N/A, not applicable.
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post-ACTH stimulation cortisol should be used to both ensure
adequate control and to detect dogs with oversuppression. In
this study, two dogs with pre-trilostane cortisol less than
40 nmol/l and post-ACTH stimulation cortisol greater than
40 nmol/l were identiﬁed. One dog responded positively to tri-
lostane withdrawal and a further case had signs consistent with
hypoadrenocorticism three months later. The results also
showed that many dogs with low post-ACTH cortisol did not
rapidly develop hypoadrenocorticism. This is in agreement with
a recent study that showed, in dogs that were well and had good
control of their HAC, that post-ACTH stimulation cortisol mea-
surements consistent with hypocortisolism at 3–6 hours did not
persist and that measurements taken at 9–12 hours were signiﬁ-
cantly higher (Midence and others 2015). Continued trilostane
therapy without altering the dose did not result in clinical evi-
dence of hypoadrenocorticism in most of this group of dogs. A
low concentration of pre-trilostane cortisol is potentially more
signiﬁcant than post-ACTH stimulation cortisol as this would
be at least 12 hours (twice-daily dosing) or 24 hours (once-daily
dosing) after the last dose of trilostane. An ACTH stimulation
test performed at 24 hours could be used to assess the true
adrenal reserve at this time (Bell and others 2006).
In previous studies that reported the use of post-ACTH
stimulation cortisol as a monitoring tool for trilostane therapy,
the clinical control was often poorly deﬁned. There are no
studies demonstrating good correlation between a systematic
evaluation of owners’ observations of clinical control and the
post-ACTH stimulation cortisol. There is also a lack of consensus
regarding the target post-ACTH stimulation cortisol concentra-
tion in trilostane-treated dogs with values varying from 15 to
250 nmol/l used to deﬁne good clinical control (Neiger and
others 2002, Ruckstuhl and others 2002, Braddock and others
2003, Wenger and others 2004, Barker and others 2005, Galac
and others 2010, Ramsey 2010).
In this study, both the pre-trilostane and three-hour post-
trilostane cortisol were better able to discriminate between dogs
that had excellent control from those that were undercontrolled.
Measurement of either or both is potentially easier and less
expensive than an ACTH stimulation test. Of the two results,
the pre-trilostane cortisol was slightly better than the three-hour
post-trilostane cortisol and had the added beneﬁt of being more
useful at signalling potential oversuppression. Using the three-
hour post-trilostane cortisol (or baseline cortisol) has previously
been evaluated as a monitoring tool. Similar to the authors’ ﬁnd-
ings, it was difﬁcult for the authors to recommend as a
stand-alone test as it indicated oversuppression in too many
cases (Burkhardt and others 2013). Further research into using a
combination of both the pre-trilostane and three-hour post-
trilostane may be useful.
In this study, the authors suggest a potential target range for
pre-trilostane cortisol of greater than 40 and less than 138 nmol/
l. A cut-off of 138 nmol/l was chosen to maximise the speciﬁcity
of results below this limit, indicating excellent control. The
lower limit of 40 nmol/l was chosen as cortisol concentra-
tions above this generally are considered to exclude hypoadre-
nocorticism in trilostane-treated dogs (Cook and Bond 2010,
Ramsey 2010, Burkhardt and others 2013). Further studies,
particularly including more dogs with trilostane-induced
hypoadrenocorticism, could alter these ranges, and it is
debatable as to whether speciﬁcity or sensitivity should be
maximised.
All cortisol assays in this study were measured in a single lab
using a validated and widely used chemiluminescent enzyme
immunoassay technique. However, there are clinically signiﬁcant
differences between alternative assays and even laboratories
using the same techniques (Russell and others 2007, Behrend
and others 2013). It is difﬁcult to extrapolate results and cut-off
values from this study to other laboratories, particularly those
using an alternative method of measuring cortisol.
There were several factors identiﬁed as having a potential
inﬂuence over the pre-trilostane, three-hour post-trilostane and
post-ACTH cortisol concentrations as well as the total owner
score. Female entire dogs had a signiﬁcantly higher pre-trilostane
and three-hour post-trilostane cortisol concentrations and total
owner scores. It has been shown that healthy entire male dogs
have lower post-ACTH simulation cortisol (Frank and others
2003) but others have not found an inﬂuence of sex and neuter
status on cortisol concentrations (Reimers and others 1990).
The number of results from female entire dogs was small, which
could have impacted on the results.
It was also interesting to note that as the trilostane dose
increased this was associated with a small increase in
post-ACTH cortisol concentrations. This further demonstrates
the difﬁculty in predicting or interpreting the results of
post-ACTH cortisol as a monitoring tool. Alternatively, it could
reﬂect that dogs requiring a higher dose are more refractory to
therapy. In addition, the longer the dogs were receiving the
current dose the lower the total owner score. This suggests that
either there is a gradual improvement in signs or there is a degree
of acceptance by the owners of their dog’s current clinical condi-
tion as being the ‘new normal’ for that dog. As the total duration
of therapy increased, both the three-hour post-trilostane and the
post-ACTH stimulation cortisol decreased, suggesting a time-
dependent suppression of both (as this was not associated with
increased total dose).
The dogs were brought to and kept in a hospital for the dur-
ation of the test (approximately four hours), and it is possible
that these environmental stresses could alter cortisol results (e.g.
a car journey might increase the pre-trilostane cortisol in a dog
that is distressed by travelling). It has previously been shown
that an examination and hospitalisation can increase urinary cor-
tisol to creatinine ratios (van Vonderen and others 1998);
however, the testing environment (including whether hospita-
lised or at home) did not markedly affect the results of ACTH
stimulation testing in normal dogs (Vial and others 1979).
Additionally, as the dogs were fed in hospital, it is possible that
this could inﬂuence trilostane absorption and therefore efﬁcacy
as it is known that stress can result in a delay in gastric empty-
ing (Enck and Holtmann 1992). It remains unknown as to what
effect this factor could have on absorption of the drug and there-
fore on the results of the pre-trilostane and post-ACTH stimula-
tion cortisol. Further investigation is warranted; however, this
factor would have little or no inﬂuence on the pre-trilostane cor-
tisol concentration. Particular care was taken to ensure that
wherever possible the dog’s normal food was provided by the
owner during the test.
TABLE 4: The final multivariable analysis model with factors retained (P<0.05)
Pre-trilostane cortisol
(nmol/l)n=110 dogs
3-hour post-trilostane cortisol
(nmol/l)n=110 dogs
Post-adrenocorticotrophic
hormone cortisol (nmol/l)n=110 dogs
Total owner score
(well dogs only)
n=93 dogs
Coefficient p Value Coefficient R2 (adj) p Value Coefficient p Value Coefficient p Value
Dose (mg/kg) 4.78 0.04
Duration at current dose (months) −0.14 0.01
Total duration of therapy (months) −1.22 0.02 −2.17 <0.01
Female entire versus all 92.85 0.01 46.43 0.04 5.102 <0.01
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One limitation of this study is that the majority of dogs
were not differentiated into adrenal-dependent or pituitary-
dependent HAC. The authors chose to include all cases of HAC
as this reﬂects the general population of dogs treated with
trilostane.
A second limitation is that the number of dogs receiving
twice-daily trilostane was small. The dose and frequency of
administration of trilostane was selected by the dogs’ primary
veterinary surgeon. However, dose frequency was not identiﬁed
in univariate analysis as having a signiﬁcant impact on any of
the three cortisol results or the total owner score. In dogs receiv-
ing trilostane once daily, the duration of suppression of cortisol
varies between 2 and 13 hours after trilostane (Bell and others
2006). In addition, there is no signiﬁcant difference between the
cortisol 12 and 24 hours after trilostane administration (Griebsch
and others 2014). It is therefore to be expected that the pre-
trilostane cortisol concentration was similar in dogs treated
with once-daily or twice-daily trilostane. However, larger case
numbers are required to draw deﬁnitive conclusions.
In this study, the deﬁnition of the dog’s clinical control was
based on the results of a standardised clinical history obtained
by means of owner questionnaire. The results of the question-
naire were assessed and categorised according to a consensus of
clinicians who were blinded to the actual cases. The clinicians
had varying levels of experience and expertise, and this could
have impacted on their ability to judge and categorise the
answers given. However, as veterinarian assessing dogs with
HAC vary in their experience, the inclusion of junior clinician
training scholars into the assessing group of clinicians better
reﬂects this population. It could be suggested that the question-
naire be used alone to make decisions regarding dose adjustment.
However, the questionnaire does not provide deﬁnitive evidence
of trilostane overdose until clinical signs develop, whereas it is
speculated that cortisol measurements may provide earlier
warning of an overdose. In addition, owners may vary in their
abilities and could underestimate or overestimate the clinical
signs at home and/or fail to recognise the signs of hypoadreno-
corticism. Furthermore, veterinarians vary in their experience of
HAC and the decisions made by specialists working in a referral
hospital using a questionnaire may not be so easily extrapolated
to a busy ﬁrst opinion mixed practice.
The questionnaire was developed from an ad hoc survey of
practising veterinarians. Ideally, this would have been tested
through a validation process, following established psychometric
approaches (Juniper and others 1996, Wiseman-Orr and others
2006). The process of development and implementation of this
questionnaire occurred during a time when tetracosactide
(Synacthen; Alliance) supply suddenly declined in the UK.
Therefore, it was not possible to test and validate this question-
naire in the time frame required to commence this study. Future
studies including development of a questionnaire following
established psychometric approaches could be considered. It
should be noted that the results obtained in this study are
similar to those obtained with other questionnaires in other lan-
guages, suggesting a common theme (Wehner and others 2013).
The majority of the dogs did not have biochemistry, electro-
lytes and haematology performed at the time of sampling,
despite the manufacturer ’s datasheet recommendations (Vetoryl,
Dechra (VMD 2016)). It is possible that some dogs had devel-
oped subclinical hyperkalaemia, which may have indicated the
development of iatrogenic hypoaldosteronism in the absence of
hypocortisolism. However, dogs can become mildly hyperkalae-
mic (subclinical) after initiation of trilostane therapy, and there
is no correlation between aldosterone concentration and potas-
sium (Wenger and others 2004, Reid and others 2014).
Additionally, there was no difference between potassium concen-
trations in dogs with post-ACTH stimulation cortisol less, or
greater, than 41 nmol/l (Ruckstuhl and others 2002). Although
trilostane can result in suppression of post-ACTH stimulation
aldosterone (Reid and others 2014), the clinical relevance and
value of frequent monitoring of electrolytes in well dogs
receiving trilostane remain unclear as both sodium and potas-
sium appear to be both in insensitive and non-speciﬁc markers
of decreased aldosterone reserve in trilostane-treated dogs. In
addition, the value of repeated haematology and biochemistry
remains questionable as many dogs treated with trilostane had
persistent haematological alterations (lymphopenia/monocyto-
sis) and increased alkaline phosphatase, despite adequate clinical
control (Ruckstuhl and others 2002, Arteaga and others 2010).
Further studies are needed to assess the value of biochemical pro-
ﬁles when pre-trilostane or post-ACTH stimulation cortisol con-
centrations are less than 40 nmol/l.
There were 17 questionnaires from 11 dogs with results that
suggested the dog was unwell. None had a cortisol concentration
less than 40 nmol/l at either point, and it was assumed that
they were unwell for another reason. These dogs were excluded
from further analysis because the dogs’ cortisol may have been
affected by another unrelated concurrent illness and therefore
may not be reliable for the assessment of clinical control (Kaplan
and others 1995).
Initially, the dogs were categorised into those with reason-
able or poor control. The initial aim was to ascertain whether
the cortisol results would be sensitive enough to differentiate
between degrees of under control. This could help clinically to
determine increments of dose changes. However, as none of the
three cortisol results was signiﬁcantly different between these
two subcategories of clinical control and both described degrees
of ineffective control, the authors elected to combine both into
one ‘undercontrolled’ category.
In conclusion, the results of this study show that the pre-
trilostane and three-hour post-trilostane cortisol concentrations
were better than the post-ACTH cortisol concentrations at dis-
criminating between dogs with excellent control and those that
were undercontrolled. No cortisol result correlated well enough
with the clinical score to be used as stand-alone monitoring test,
and it may be that the only effective monitoring tool would be
one based on clinical signs. However, the pre-trilostane cortisol
was the objective measurement that had the most potential to
balance safety with effective therapy. Further studies fully asses-
sing the repeatability of the cortisol results and the inclusion of
dogs that are unwell due to iatrogenic hypoadrenocorticism are
needed before this novel method can be used as an adjunctive
monitoring tool.
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